Quarterly Revenue
The latest quarterly quarterly revenue is $761.70M with a quarterly period change of (2.82%). Quarterly revenue is the total sales generated during the latest fiscal quarter.
PODD Quarterly Revenue
Reported quarterly revenue; no daily interpolation.
Quarterly Revenue History
| Period | Quarterly Revenue | % Change |
|---|---|---|
| Q1 2026 | $761.70M | (2.82%) |
| Q4 2025 | $783.80M | +10.97% |
| Q3 2025 | $706.30M | +8.81% |
| Q2 2025 | $649.10M | +14.08% |
| Q1 2025 | $569.00M | (4.77%) |
| Q4 2024 | $597.50M | +9.85% |
| Q3 2024 | $543.90M | +11.34% |
| Q2 2024 | $488.50M | +10.60% |
| Q1 2024 | $441.70M | (13.36%) |
| Q4 2023 | $509.80M | +17.82% |
| Q3 2023 | $432.70M | +9.13% |
| Q2 2023 | $396.50M | +10.72% |
| Q1 2023 | $358.10M | (3.14%) |
| Q4 2022 | $369.70M | +8.48% |
| Q3 2022 | $340.80M | +13.83% |
| Q2 2022 | $299.40M | +1.35% |
| Q1 2022 | $295.40M | (4.00%) |
| Q4 2021 | $307.70M | +11.65% |
| Q3 2021 | $275.60M | +4.71% |
| Q2 2021 | $263.20M | +4.32% |
| Q1 2021 | $252.30M | +2.52% |
| Q4 2020 | $246.10M | +5.17% |
| Q3 2020 | $234.00M | +3.40% |
| Q2 2020 | $226.30M | +14.29% |
| Q1 2020 | $198.00M | (5.44%) |
| Q4 2019 | $209.40M | +9.00% |
| Q3 2019 | $192.12M | +8.46% |
| Q2 2019 | $177.14M | +11.02% |
| Q1 2019 | $159.56M | (3.25%) |
| Q4 2018 | $164.91M | +9.15% |
| Q3 2018 | $151.08M | +21.58% |
| Q2 2018 | $124.26M | +0.55% |
| Q1 2018 | $123.58M | (5.32%) |
| Q4 2017 | $130.52M | +7.18% |
| Q3 2017 | $121.78M | +10.95% |
| Q2 2017 | $109.76M | +7.91% |
| Q1 2017 | $101.71M | (1.80%) |
| Q4 2016 | $103.58M | +9.17% |
| Q3 2016 | $94.87M | +8.64% |
| Q2 2016 | $87.33M | +7.53% |
| Q1 2016 | $81.21M | (18.88%) |
| Q4 2015 | $100.12M | +14.68% |
| Q3 2015 | $87.30M | +15.50% |
| Q2 2015 | $75.59M | +23.48% |
| Q1 2015 | $61.22M | (15.64%) |
| Q4 2014 | $72.56M | (3.23%) |
| Q3 2014 | $74.98M | +4.13% |
| Q2 2014 | $72.01M | +4.12% |
| Q1 2014 | $69.16M | +0.92% |
| Q4 2013 | $68.53M | +12.16% |
| Q3 2013 | $61.10M | +1.68% |
| Q2 2013 | $60.09M | +4.77% |
| Q1 2013 | $57.36M | (0.82%) |
| Q4 2012 | $57.83M | +5.62% |
| Q3 2012 | $54.75M | +7.28% |
| Q2 2012 | $51.03M | +6.87% |
| Q1 2012 | $47.75M | +1.19% |
| Q4 2011 | $47.19M | +5.83% |
| Q3 2011 | $44.59M | +38.44% |
| Q2 2011 | $32.21M | +13.99% |
| Q1 2011 | $28.26M | +1.77% |
| Q4 2010 | $27.77M | +9.08% |
| Q3 2010 | $25.45M | +10.98% |
| Q2 2010 | $22.94M | +10.24% |
| Q1 2010 | $20.81M | +2.95% |
| Q4 2009 | $20.21M | +7.88% |
| Q3 2009 | $18.73M | +28.17% |
| Q2 2009 | $14.62M | +17.23% |
| Q1 2009 | $12.47M | +5.13% |
| Q4 2008 | $11.86M | +17.32% |
| Q3 2008 | $10.11M | +36.31% |
| Q2 2008 | $7.42M | +11.18% |
| Q1 2008 | $6.67M | +52.97% |
| Q4 2007 | $4.36M | +15.04% |
| Q3 2007 | $3.79M | +18.03% |
| Q2 2007 | $3.21M | +59.96% |
| Q1 2007 | $2.01M | +22.36% |
| Q4 2006 | $1.64M | +143.47% |
| Q3 2006 | $674,000 | +0.00% |
| Q2 2006 | $674,000 | +0.00% |
| Q1 2006 | $674,000 | - |
| Q4 2005 | $0 | - |
| Q3 2005 | $0 | - |
| Q2 2005 | $0 | - |
| Q1 2005 | $0 | - |
About Insulet Corp.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ashley A. McEvoy